Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)

C. M L van Herpen, L. D. Locati, J. Buter, J. Thomas, J. Bogaerts, D. Lacombe, P. de Mulder, A. Awada, L. Licitra, J. Bernier, J. B. Vermorken

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This phase II study was conducted to determine the antitumour activity of gemcitabine in adenoid cystic carcinoma (ACC). Patients and methods: Patients with progressive and/or symptomatic, recurrent and/or metastatic ACC were treated with gemcitabine 1250 mg/m2 intravenous (i.v.) on days 1 and 8 of each 21-day cycle. Each cycle was repeated every 3 weeks in the absence of disease progression for a minimum of four cycles and a maximum of 12 cycles. Results: Among 21 ACC patients, there were no objective responses. Eleven patients had a stable disease, of which ten patients for more than 6 months, and eight had a progressive disease after 4 cycles. Gemcitabine was well tolerated by most patients. Conclusion: We conclude that gemcitabine is not an active drug in ACC.

Original languageEnglish
Pages (from-to)2542-2545
Number of pages4
JournalEuropean Journal of Cancer
Volume44
Issue number17
DOIs
Publication statusPublished - Nov 2008

Keywords

  • Adenoid cystic carcinoma
  • Gemcitabine
  • Head and neck cancer
  • Salivary gland tumours

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)'. Together they form a unique fingerprint.

Cite this